FDA Gives Nod to Aflibercept for Colon Cancer
(MedPage Today) — The FDA has approved the angiogenesis inhibitor aflibercept (Zaltrap) for patients with previously treated metastatic colorectal cancer.
(MedPage Today) — The FDA has approved the angiogenesis inhibitor aflibercept (Zaltrap) for patients with previously treated metastatic colorectal cancer.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.